Nabla Bio

Nabla Bio is a biotechnology company that develops integrated artificial intelligence (AI) and wet-lab technologies for the atomically precise design of protein-based therapeutics. The company specializes in designing antibodies targeting multipass membrane proteins such as G protein-coupled receptors (GPCRs), ion channels, and transporters. These proteins play a central role in controlling cell behavior but have long been considered challenging targets for drug development due to their membrane-integrated nature, limited extracellular availability, conformational dynamics, and structural similarity across targets.

Nabla Bio's proprietary generative protein design platform enables the accurate design of conformation and target-selective antibody binders against these previously inaccessible targets. The platform combines cutting-edge AI models, including natural language processing algorithms adapted for protein design, with high-throughput screening capabilities to generate predictive biophysical fingerprints for millions of antibodies in a single step. This integrated approach allows Nabla Bio to design developable, selective, and functionally active protein drugs with a degree of structural precision not previously possible.

Through a series of partnerships with leading pharmaceutical companies, Nabla Bio has demonstrated the broad applicability of its platform beyond multipass membrane protein targets. For instance, the company has designed novel cytokines, complex multi-domain antibodies, and receptor traps with greater in vitro activity and developability than leading drugs on the market. These results represent an important step toward translating generative protein design into clinical therapies and highlight Nabla Bio's expanding capabilities.

The company was founded in December 2021 based on the pioneering work of co-founder and CEO Surge Biswas on the first protein language models published in Nature Methods and Nature Biotechnology. Since its inception, Nabla Bio has raised USD 37 million in funding from investors such as Radical Ventures, Khosla Ventures, and Zetta Venture Partners. In May 2024, the company secured a USD 26 million Series A financing round led by Radical Ventures.